REG-Bioventix Plc: Appointment of CFO

BioventixAnnouncement

02/07/2020 06:15

Bioventix plc
(“Bioventix” or the “Company”)

Appointment of CFO

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that Bruce Hiscock will join the Board as
Chief Financial Officer with immediate effect.

Mr Hiscock was previously CEO and CFO of everyLIFE Technologies, a technology
business delivering digital care planning solutions to social care providers.
Prior to this he was the Managing Director of MITIE Security Systems, the CEO
of Protec plc, an AIM listed security and technology services business, and
held several CFO roles at both fast-growing listed and private companies over
a 30-year career. Mr Hiscock is a member of the Institute of Chartered
Accountants of Scotland.

The following information regarding the appointment of Bruce Edward Heath
Hiscock (aged 61) is required to be disclosed under Schedule 2(g) of the AIM
Rules for Companies:

 Current directorships and/or partnerships  Former directorships and/or partnerships  (within the last five years)  
 n/a                                        everyLIFE Technologies Limited Warnborough Associates Limited           

There are no further disclosures to be made under Schedule 2(g) of the AIM
Rules for Companies.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved